Orris

Tranexamic acid dosage

Reading File
Finding Sources
Searching the Web

tranexamic acid dosage indications 2025

Reading File
Reading File
Reading File
Reading File
Finding Sources
Here is a comprehensive breakdown of tranexamic acid (TXA) dosing by indication:

Tranexamic Acid - Dosage by Indication

Mechanism of Action

TXA is an antifibrinolytic agent. It reversibly binds to lysine-binding sites on plasminogen, blocking plasmin formation and preventing fibrin degradation. This stabilizes clots and reduces bleeding.

1. Trauma / Massive Hemorrhage (IV)

The standard regimen is:
  • 1 g IV over 10 minutes (bolus), then
  • 1 g IV over 8 hours (infusion)
Must be given within 3 hours of injury. Benefit is time-sensitive:
  • Within 1 hour: 32% relative risk reduction in death from bleeding
  • 1-3 hours: 21% relative risk reduction
  • After 3 hours: less effective and potentially harmful
  • Tintinalli's Emergency Medicine, p. 1548; Bailey & Love's Short Practice of Surgery, p. 8081

2. Heavy Menstrual Bleeding (Oral - FDA-approved)

  • 1300 mg (two 650 mg tablets) PO three times daily for up to 5 days during menstruation (3900 mg/day)
  • Alternative dosing cited in some references: 1 g four times daily for 4 days
Renal dose adjustment for oral TXA (menorrhagia):
Serum CreatinineDose
1.4 - 2.8 mg/dL1300 mg PO twice daily x 5 days
2.8 - 5.7 mg/dL1300 mg PO once daily x 5 days
> 5.7 mg/dL650 mg PO once daily x 5 days

3. Von Willebrand Disease / Hemophilia (Oral or IV)

  • Oral: 15-25 mg/kg three times daily
  • IV: 15 mg/kg three times daily
  • Particularly useful as adjunct for dental procedures (7-10 days)
  • Goldman-Cecil Medicine, p. 1573-1574

4. Postpartum Hemorrhage (IV)

  • 1 g IV when initial uterotonic therapy fails
  • ACOG recommends considering TXA when standard medical therapy for PPH is insufficient
  • TXA crosses the placenta and enters breast milk
  • Miller's Anesthesia 10e, p. 2835-2838

5. Cardiac Surgery (Pediatric/Neonatal - IV)

  • Neonates/young children: 30 mg/kg IV bolus, then 10 mg/kg/h infusion
  • Older children/adults (cardiac): 10 mg/kg IV bolus, then 10 mg/kg/h infusion
  • High doses should be avoided due to risk of seizures
  • Miller's Anesthesia 10e, p. 4673

6. Orthopedic Surgery (Hip/Knee Arthroplasty)

  • Used to reduce operative blood loss; specific dose often protocol-driven (IV or topical)
  • Same general IV regimens apply; a second dose may be given at wound closure

7. Epistaxis

  • 1.5 g PO three times daily (shown to reduce severity and risk of re-bleeding)
  • Scott-Brown's Otorhinolaryngology, p. 4873-4884

Renal Impairment - General IV Dosing

TXA is renally excreted; dose reduction is required in renal impairment. Ureteral obstruction by clots is a risk in upper urinary tract bleeding - use with caution.

Key Safety Points

  • Minimal thrombotic risk even in high-risk populations (trauma, PPH, orthopedic surgery)
  • Do not use if active thromboembolic disease
  • Seizure risk at high doses (especially in cardiac surgery)
  • Avoid or dose-reduce in renal impairment

According to Malaysian MOH guidelines

Searching the Web

Malaysia MOH tranexamic acid dosage guidelines clinical practice

Searching the Web

Malaysia Ministry of Health tranexamic acid CPG trauma postpartum hemorrhage dosing

Reading Web Page

https://www.e-mjm.org/2019/v74n4/tranexamic-acid.pdf

Searching the Web

site:moh.gov.my tranexamic acid CPG guidelines

Reading Web Page

https://www.moh.gov.my/images/04-penerbitan/garis-panduan-kk…

I now have detailed, direct Malaysian MOH source material. Here is a comprehensive answer based specifically on Malaysian MOH documents:

Tranexamic Acid Dosage - Malaysian MOH Guidelines

The following is drawn from three official Malaysian MOH sources:
  1. CPG: Management of Abdominal Trauma in Adults (MaHTAS, MOH Malaysia)
  2. Trauma Life Support Malaysia (TLSM) Student Provider Manual v2.3.25 (MOH Malaysia)
  3. Pre-Hospital Care Ambulance Services (PHCAS) Guideline - published in the Medical Journal of Malaysia (2019)

Standard Adult Dosing (Trauma)

ComponentDoseRoute & Rate
Loading dose1 gIV over 10 minutes
Maintenance dose1 gIV infusion over 8 hours
"Tranexamic acid can be administered via the intravenous route, at a dose of 1 gram given as a slow bolus (slow push) followed by 1 gram over 8 hours."
  • TLSM Manual v2.3.25 (MOH Malaysia)

Indications (CPG Abdominal Trauma - Table 1)

TXA should be administered within 3 hours of injury in patients with:
  • Suspected haemorrhage
  • Systolic BP < 90 mmHg
  • GCS ≤ 12

Paediatric Dosing

The TLSM manual specifies a weight-based dose for children:
  • 15 mg/kg IV within 3 hours of injury
  • TLSM Manual v2.3.25, p. 297 (Paediatric section)

Pre-Hospital (PHCAS) Dosing

For ambulance services delivering TXA in the field:
  • 1 g (from a 100 mg/mL, 10 mL vial) administered as a slow IV push
  • Must be given as early as possible, no later than 3 hours after trauma
  • Criteria are divided into inclusion, exclusion, and "requires medical direction" categories
Inclusion criteria (any one of the following - give TXA directly):
  • Hypotension (SBP < 100 mmHg)
  • Tachycardia (HR > 110 bpm)
  • Suspected internal bleeding
  • Need for tourniquet to control limb haemorrhage
  • Evidence of base of skull fracture with active ear or nasal bleed
  • Entrapment (trapped >30 minutes requiring mechanical rescue)

Critical Time Rule (All MOH Guidelines)

All Malaysian MOH sources consistently state:
  • TXA must be given within 3 hours of injury
  • Administration after 3 hours is not recommended and may be harmful
  • The MOH KPI requires TXA to be given within 60 minutes of ED arrival (including pre-hospital dose time)

Where TXA is NOT Given (Exclusion Criteria per PHCAS/MOH)

  • Known allergy to TXA
  • Known pro-coagulation disorders (PE, APS, cavernous sinus thrombosis, DVT)
  • Injury occurred more than 3 hours ago
  • Age < 18 years (in the ED KPI criteria; weight-based dose used in TLSM for paediatrics)

Indication Beyond Trauma (MOH CPG Intracerebral Haemorrhage, 2025)

The MOH CPG for Spontaneous Intracerebral Haemorrhage (2025) references TXA at 1 g IV over 10 minutes followed by 1 g over 8 hours in the context of NOAC-related ICH (citing the TICH-NOAC trial), though it did not show benefit in that specific context.

Summary Table

SettingDoseTiming
Adult trauma (pre-hospital & ED)1 g IV bolus over 10 min + 1 g IV over 8 hWithin 3 hours of injury
Paediatric trauma15 mg/kg IVWithin 3 hours of injury
Pre-hospital (PHCAS ambulance)1 g slow IV pushAs early as possible, ≤3 h

For AUB

Searching the Web

Malaysia MOH CPG abnormal uterine bleeding tranexamic acid guidelines moh.gov.my

Searching the Web

Malaysia MOH "abnormal uterine bleeding" OR "AUB" tranexamic acid dosage clinical practice guideline

Reading Web Page

https://www.e-mjm.org/2022/v77n3/abnormal-uterine-bleeding.p…

Searching the Web

"moh.gov.my" "heavy menstrual bleeding" OR "menorrhagia" CPG tranexamic acid

I now have sufficient information to give a clear, well-sourced answer. Here is what the Malaysian MOH and Malaysian clinical sources specifically say about TXA for AUB:

Tranexamic Acid for AUB - Malaysian MOH / Malaysian Clinical Guidance

Important note: There is no standalone Malaysian MOH CPG dedicated solely to AUB/HMB as a published CPG from MaHTAS. The guidance comes from a combination of Malaysian gynaecology practice references, the Medical Journal of Malaysia (2022) AUB review by Malaysian O&G specialists, and local O&G practice guidelines used in Malaysian hospitals.

Role of TXA in AUB

TXA is classified as a non-hormonal, first-line medical option for AUB, specifically for:
  • Heavy Menstrual Bleeding (HMB) / AUB-HMB - ovulatory type with heavy flow
  • AUB-COEIN categories (Coagulopathy, Ovulatory dysfunction, Endometrial, Iatrogenic, Not classified)
  • Used during menses only (not continuous)

Dosing for AUB (Malaysian O&G Practice Reference)

Chronic / Outpatient (Oral)

IndicationDoseDuration
Heavy menstrual bleeding (ovulatory AUB)1 g TDS or QID orallyDuring menses (first 3-4 days)
Anovulatory AUB with heavy flow1 g TDS or QID orally (adjunct to progestogen)During heavy bleeding days
"Use 1 gm tds or qid" - Malaysian O&G Practice Reference, Dr Lee Say Fatt FRCOG, Subang Jaya Medical Centre
The MJM 2022 AUB review by Malaysian O&G specialists confirms TXA reduces menstrual blood loss by approximately 50% and notes:
  • Side effects are minimal
  • GI side effects (nausea, diarrhoea) occur in a third of women at 3-6 g/day
  • Limiting treatment to the first 3-4 days minimises side effects, as 90% of blood loss occurs in the first 3 days of flow

Acute / Inpatient (IV)

For acute heavy AUB requiring admission:
RouteDoseNotes
IV1 g QIDSwitch to oral as bleeding decreases
Oral1 g TDS or QIDOnce bleeding is controlled

Where TXA Fits in the AUB Treatment Algorithm (Malaysian Practice)

AUB TypeTXA Role
Ovulatory AUB (HMB) - regular cycles, heavy flowFirst-line non-hormonal option (alongside NSAIDs)
Anovulatory AUB - irregular cycles, heavy flowAdjunct to progestogens, for those with heavy flow
AUB with desire for contraceptionLNG-IUS preferred; TXA as adjunct
AUB in coagulopathy (e.g. VWD)TXA used alongside desmopressin

Contraindications (Malaysian Practice)

  • Known thromboembolic disease (DVT, PE, stroke)
  • Active intravascular clotting
  • Renal impairment (dose reduce or avoid)
  • Do not combine with COC pills without caution - theoretical increased thrombosis risk (though evidence does not show significantly increased VTE in practice)

Key Practical Points for Malaysian Clinical Use

  1. TXA is widely available in Malaysian MOH hospitals and on the Malaysian National Essential Medicines List
  2. Prescribed only during menstruation, not continuously
  3. Reduces bleeding by ~50%; clinical effect is seen from the first cycle
  4. Does not affect ovulation - safe if the patient is trying to conceive
  5. No dose titration needed in normal renal function
This is a shared conversation. Sign in to Orris to start your own chat.